Paradeep Q1: consolidated PAT ₹393 Cr up ~24% YoY on merged base, revenue +36%
PAT +23.9% YoY · revenue +36% · margins compressing
₹6,124.25 Cr
+36% YoY
₹392.54 Cr
+23.9% YoY
6.39%
-0.4pp YoY
₹3.78
Paradeep Phosphates opened FY27 with consolidated revenue of ₹6,124.25 Cr and net profit of ₹392.54 Cr (EPS ₹3.78) for the June 2026 quarter. On a like-for-like basis — comparing against the merger-restated year-ago quarter (revenue ₹4,503.50 Cr, PAT ₹316.75 Cr) — that is +36.0% on the topline and +23.9% on PAT. Stripping the ₹21.80 Cr one-off exceptional gain (a write-back of gratuity/leave liability on the new Labour Codes), underlying PAT growth is closer to ~19%, so this is solid rather than spectacular profit growth riding on a strong topline. A caution on the optics: our records carry the pre-merger Q1FY26 base (₹3,754.06 Cr revenue, ₹255.85 Cr profit), against which the print looks like +63% revenue / +53% PAT — but that compares the merged entity to the old standalone Paradeep and is not apples-to-apples; the filing itself restates the year-ago to fold in Mangalore Chemicals, and the honest read is +36% / +24% (~19% adjusted).
Q1 FY-2027 vs prior quarters
The quarter is seasonally the strongest for fertiliser makers (kharif stocking), so the +30% QoQ revenue and the optically huge +152% QoQ jump in PAT off a weak ₹155.60 Cr March quarter are largely seasonality and should not be read as a step-change. Margins actually thinned year-on-year on a like-for-like basis: net margin was ~6.4% versus ~7.0% in the restated year-ago, and EBITDA margin compressed to ~12.1% from ~13.7%, with the squeeze sitting in raw-material and traded-goods cost — cost of materials plus stock-in-trade purchases ran hot even as revenue scaled. Finance costs also rose to ₹131.70 Cr (from ₹104.35 Cr), reflecting the enlarged, capex-heavy balance sheet.
The stock went into the print at ₹139.21, up 3.5% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records.
Management refrained from providing specific quantitative guidance for FY27 due to significant geopolitical volatility and high raw material prices. However, they expect benefits from newly commissioned Sulfuric Acid plants and an ongoing Phos Acid expansion to materialize in FY27. The company remains committed to its
Management offered no quantitative FY27 guidance on the Q4 concall (May 2026), citing geopolitical volatility and high raw-material prices, but pointed to benefits from newly commissioned sulphuric acid capacity and an ongoing phos-acid expansion materialising through FY27 alongside a planned ₹600 Cr capex; the +19% adjusted operating profit growth this quarter is directionally consistent with that backward-integration thesis, though it is early. No brokerage consensus estimate for the quarter surfaced in a web check, so the print cannot be graded beat/miss versus the Street. On the corporate front, the quarter carried mostly housekeeping (trading-window closure, the ₹20.57 Cr income-tax refund in May) but also an NCLAT order rejecting the company's entry-tax exemption appeal in May — an unquantified contingent liability worth tracking. Standalone and consolidated tell the same story (PAT ₹392.60 Cr vs ₹392.54 Cr), the ₹0.06 Cr associate loss being immaterial.
W1
Whether the ~19% adjusted PAT growth holds without one-offs — this quarter leaned on a ₹21.80 Cr Labour Code exceptional gain
W2
Margin trajectory: EBITDA margin ~12.1% vs ~13.7% year-ago — monitor if sulphuric/phos-acid ramp reverses the raw-material squeeze in H2FY27
W3
Financial fallout from the May NCLAT entry-tax exemption rejection, currently unquantified in the P&L
Clean, machine-generated statement; all arithmetic ties. Two adjustments matter: (1) Q1FY26 comparatives are RESTATED to include Mangalore Chemicals (MCFL) merger (appointed date 1-Apr-2024), so like-for-like YoY uses restated consol rev ₹4,503.50 Cr / PAT ₹316.75 Cr — NOT the ₹3,754.06 Cr / ₹255.85 Cr pre-merger figures in our DB (filing discloses ex-scheme Q1FY26 rev ₹3,754.06 Cr, PBT ₹341.83 Cr). (2) ₹21.80 Cr POSITIVE exceptional item this quarter = write-back on gratuity/leave reassessment under new Labour Codes; year-ago had none. Consol also includes ₹0.06 Cr associate loss. EPS not annualised.
Strong volume growth masked by raw-material headwinds and margin normalization
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met prior guidance: backward-integration benefits realized (sulph acid +32%, phos acid +7%). Phosphoric acid Phase-I on track (1 lakh tons by Dec). New quantitative guidance ₹5,000/MT normalized EBITDA; credible if raw material stabilizes and government support continues.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Company delivered 63% revenue growth with backward-integration benefits (sulph acid +32%, phos acid +7%) and market-share gains (13% volume growth vs 1% industry). EBITDA per ton ₹7,000 is strong but inventory-aided; normalized ₹5,000/MT guidance signals -29% margin compression if raw-material costs remain elevated. Near-term headwind: sulphur $1,000+/MT (up $150 in 3 months), 70–75% global trade via geopolitical risk zone, government DAP price caps limiting pass-through. Long-term strategy credible (₹3,500+ Cr capex, AlF3 diversification), but dependent on execution and macro stabilization. Key risk: subsidy receivable ₹4,600 Cr (75% of quarterly PAT) exposes cash flow to government timing.
₹6124.3 Cr
Revenue · +63.1% YoY₹392.5 Cr
Reported PAT · +53.4% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Revenue increased 36% YoY to ₹6,124 Cr
MISSDelivered result shows 63.1% YoY revenue growth to ₹6,124 Cr
Sulphuric acid production 32% higher YoY
METDelivered backward integration benefits; sulphuric acid capacity fully utilized
Phosphoric acid production 7% higher YoY
METConsistent with phase-I expansion narrative and capacity buildup
EBITDA per ton ₹7,000; normalized ₹5,000 after cost stabilization
METEBITDA ₹742 Cr / 9.85 L tons = ₹7,530/MT (vs prior ₹6,500). Inventory benefit acknowledged.
Traded volumes to offset production gaps; overall market share maintained
METPragmatic hedging; 500k tons imports secured for rabi. DAP volume +55%, NPK -9% but farmer sales +6%.
Earnings quality
What changed since the last call
Backward integration materializing ahead of guidance
UpgradeSulph acid +32% YoY, phos acid +7% YoY; capacity fully utilized. Prior guidance: 'benefits expected in FY27' → realized.
Product mix tactical shift to DAP
NeutralDAP volume +55% (₹1,350/bag govt cap), NPK –9% volume but +6% farmer sales. Optimization for profitability amid subsidy caps; long-term NPK focus unchanged.
Non-subsidy diversification approved
Upgrade₹250 Cr AlF3 plant capex approved (15,000 MTPA, ₹50+ Cr EBITDA). Long-term target 20% EBITDA from non-subsidy. New strategic pillar beyond fertilizer.
Normalized EBITDA guidance formalized
NeutralPrior: vague 'benefits from backward integration' → Current: ₹5,000/MT normalized (vs ₹7,000 Q1 aided by inventory). New quantitative anchor; dependent on cost stabilization.
Capacity ramp timelines reaffirmed
MaintainedPhos acid Phase-I (5→7L tons) on track: 1L by Dec, 1L by Aug FY28. Contracts awarded, equipment ordered. No delays vs prior guidance.
The Q&A
Analysts pressed on raw-material sourcing strategy, sustainability of ₹5,000/MT normalized margin, and AlF3 demand validation. Management transparent on sulphur volatility (spot basis, no hedges) but withheld cost basis (commercially sensitive). Held firm on expansion timelines and long-term strategy despite acknowledging unprecedented geopolitical disruption.
Raw material sourcing Q2 — Prashant Biyani, Elara Securities
PartialEvaluating options. Targeting ~70% phos acid capacity utilization; backward integration still strategic. Augmenting via imported DAP/NPK for rabi.
AlF3 plant capex & returns — Prashant Biyani, Elara Securities
Answered22–24 months (Mar 2028 target). ₹180–200 Cr annual revenue, ₹50+ Cr EBITDA. 15,000 MTPA capacity. B2B sales to aluminum smelters in Odisha.
Product mix: DAP +55%, NPK –9% — Aman Kothari, Aequitas Investments
AnsweredDAP more profitable due to govt subsidy structure. Tactical Q1 shift; long-term strategy remains NPK-focused. Farmer NPK sales +6% (price-driven volume decline offset). Price normalization could reverse shift.
EBITDA sustainability — Saumil Shah, Paras Investments
Answered₹7,000 Q1 aided by low-cost inventory. Realistic normalized EBITDA ₹5,000/MT per year. Once expansions complete (2–2.5 yrs), should reach ₹7,000+ sustained.
Market share gains vs flat industry — Dev Gulwani, Care PMS
AnsweredBalanced regional presence (N, E, W, S), strong brands (Jai Kisaan Navratna, Mangala), backward integration (OCP rock secured), product mix flexibility. Grew farmer sales 15–16% vs 1% industry.
Sulphur pricing trends — Vignesh Iyer, Sequent Investments
PartialQ1 average $850/MT, now $1,000+/MT. No long-term contracts (volatility prevents). Currently spot-basis only. Commercially sensitive to disclose exact cost.
Expansion timeline tracking — Dhruv Muchhal, HDFC AMC
AnsweredPhos acid Phase-I: 5→6L tons by Dec, 6→7L tons by Aug FY28 (on track). Equipment ordered, contracts awarded. Big expansion (3L tons) starting Q2 FY29 (no delay).
Capex and normalized EBITDA guidance — Manish Mahawar, Antique Stock Broking
PartialBig capex FY29–30 starting Q2 FY29 (phased). Sustainable ₹5,000/MT target; depends on cost normalization and government coordination on subsidy support.
Subsidy receivable and collections — Archit Agarwal, Steptrade Capital
AnsweredOutstanding subsidy ₹4,600 Cr as of 30 Jun. Q1 received ₹2,650 Cr (22% higher YoY). Operating cash flow positive; inventory liquidated.
NPK adoption drivers beyond pricing — Aman Kothari, Aequitas Investments
AnsweredFarmer awareness on soil health and balanced fertilization. Sulphur deficiency in soil makes NPK valuable. Market 24M tons phosphate (10M DAP, 14M NPK). If govt removes DAP MRP cap, portfolio rebalances.
Guidance
No explicit FY27 revenue target. Volume growth expected offset by DAP mix shift and trading.
LowQ1 ₹6,124 Cr; company deferring full-year guidance due to macro volatility. Signaling volume discipline over revenue headline.
EBITDA per MT: ₹5,000 normalized; ₹7,000+ once expansions complete (2–2.5 yrs).
MediumQ1 ₹7,000 aided by inventory. Normalized ₹5,000 assumes raw-material stabilization + government subsidy support. Dependent on external factors.
FY27: Phos acid Phase-I (5→6L by Dec, 6→7L by Aug FY28). Granulation debottleneck 3.7→4L by Dec. AlF3 plant start (₹250 Cr total).
HighContracts awarded, equipment ordered. Execution tracking on schedule. No delays signaled.
FY29–30: Big expansion 3L tons phos+sulph acid (₹3,500–3,600 Cr). Start Q2 FY29 (mid-fiscal).
MediumMulti-year project. Final commercial discussions ongoing. Timing and cost subject to macro conditions (raw-material prices, financing).
Risks the call surfaced
Raw material volatility
HighSulphur prices +18% Q1 avg ($850/MT), now $1,000+/MT. 70–75% global sulphur/ammonia trade via Strait of Hormuz (geopolitical risk). Company on spot basis only, no hedges.
Subsidy receivable concentration
High₹4,600 Cr outstanding subsidy (75% of Q1 PAT ₹392.5 Cr). Government payment delays would severely impact working capital and liquidity. Collections volatile by policy.
Government price caps
HighDAP MRP capped at ₹1,350/bag by govt. NPK prices ₹2,100–2,500/bag (uncapped). Cap prevents passing raw-material cost inflation to farmers; margins compressed.
Capacity project execution
Medium₹3,500–3,600 Cr big-expansion capex (3L tons phos+sulph acid) over FY29–30. Timing critical for achieving ₹7,000+ EBITDA/MT. Delays would defer earnings uplift.
Normalized EBITDA miss risk
Medium₹5,000/MT normalized EBITDA guidance depends on raw-material stabilization + government support. Q1 ₹7,000 via inventory benefit; normalization is -29% drag. Risk: if costs stay elevated or gov support withheld, EBITDA undershoots.
Management
Score 7/10. Transparent on raw-material volatility and hedging strategies (tactical DAP shift, 500k tons imports secured, trading volumes). Some commercial sensitivity (sulphur cost basis, AlF3 supplier details withheld). Clear on expansion timelines, phased ramps, and inventory-benefit disclaimer. Answers detailed but occasionally qualify on government support dependency. Strong on backward integration (sulph acid +32%, phos acid +7% delivered as expected). Phase-I phosphoric-acid expansion timelines being met (contracts awarded, equipment ordered). Debt reduction (₹700 Cr paydown) despite macro headwinds shows operational discipline. Met prior FY26 guidance on backward-integration benefits.
1 · Dec 2026 (Q3 FY27)
Phosphoric acid Phase-I: 5→6 lakh tons ramp. Granulation debottleneck 3.7→4 lakh tons target.
2 · Aug 2027 (Q1 FY28)
Phosphoric acid Phase-I final: 6→7 lakh tons capacity online. Capacity utilization expansion.
3 · Q2 FY29 (Sep 2028)
Big expansion capex ramp start: ₹3,500–3,600 Cr, 3 lakh tons phos+sulph acid capacity. Multi-quarter build.
Key risk: subsidy receivable ₹4,600 Cr (75% of quarterly PAT) exposes cash flow to government timing.
Growth Lifts, But Margins Normalize—And Subsidy Risk Looms
Paradeep delivered 63% revenue growth and 53% PAT growth on backward-integration gains (sulph acid +32%, phos acid +7%). But normalized EBITDA guidance of ₹5,000/MT signals -29% margin compression as raw-material costs stabilize, and a ₹4,600 Cr subsidy receivable (75% of PAT) exposes cash flow to government payment timing.
₹6,124 Cr
+63.1% YoY
₹392.5 Cr
+53.4% YoY
9.85 L tons
+4% YoY
₹7,000
vs ₹5,000 normalized
Paradeep's Q1 looks like a winner on the headline—63% revenue growth, strong volume gains, and a return to profitability momentum. Dig into the P&L, though, and the story is messier: backward integration is finally delivering the goods (sulphuric acid production up 32%, phosphoric acid up 7% year-on-year, both at full capacity), but raw-material costs are rising fast, and the company's own guidance has already baked in a brutal -29% margin compression the moment inventory benefits fade. The subsidy receivable—₹4,600 crore, or 75% of the quarter's entire profit—sits in limbo waiting for government payments, and that's a working-capital sword that could cut either way.
Claims vs. what holds up
Revenue increased 36% YoY
ContradictedDelivered ₹6,124 Cr (+63.1% YoY)
Sulphuric acid production +32% YoY
SupportedBackward integration at 100% capacity utilization; volumes confirm
Phosphoric acid production +7% YoY
SupportedPhase-I expansion narrative consistent; capacity fully deployed
EBITDA per ton ₹7,000; normalized ₹5,000/MT
SupportedQ1 ₹742 Cr EBITDA ÷ 9.85 L tons = ₹7,530/MT; inventory benefit acknowledged
DAP volume +55%, NPK –9%; market share maintained
Supported9.85 L tons (+4% YoY) vs +1% industry phosphatic; farmer sales +15–16%
The revenue-growth claim stands out as an error—management stated 36% on the call, but the delivered result is 63.1%. Whether this was a slip or a data mix-up, it's the kind of misstatement that should worry an analyst listening live. Everything else checks: backward integration is real and working, volumes are strong, and the EBITDA guidance of ₹5,000/MT normalized (down from Q1's ₹7,000/MT) is appropriately conservative, reflecting low-cost inventory liquidation in the quarter.
Where the margin compression lives
Of the ₹7,000 per ton EBITDA in Q1, roughly ₹2,000 came from burning through low-cost inventory—a one-time tailwind. Management's normalized target of ₹5,000/MT assumes sulphur settles, the government sustains support, and raw-material inflation doesn't accelerate further. Sulphur, though, moved from $850/MT in Q1 to over $1,000/MT in the current spot market. That's an 18% jump in three months, and it directly compresses the margin math. Spot exposure (no hedges) means every ₹10 swing in sulphur hits the quarterly EBITDA target hard.
What changed on this call
AlF3 plant approved: ₹250 Cr capex for aluminum fluoride production (15,000 MTPA). Target 22–24 months to commission. ₹50+ Cr EBITDA run-rate. Diversification away from subsidy-dependent fertilizer.
Phosphoric acid Phase-I on track: 5→7 lakh tons ramping. 1 lakh tons by Dec FY27, final 1 lakh by Aug FY28. Contracts awarded, equipment ordered. No delays.
Product mix shifted to DAP: Volume +55% Q1 (govt-capped at ₹1,350/bag). NPK –9% volume, but farmer sales +6% (price increases). Tactical Q1 optimization; long-term NPK focus unchanged.
Normalized EBITDA formalized: Prior guidance was vague ('benefits expected in FY27'). Now explicit: ₹5,000/MT normalized, ₹7,000+ once expansions complete (2–2.5 years).
How the market has reacted
The stock popped 12.45% on day 1 of the result announcement with 40.3% delivery, indicating strong retail conviction. The move held partially—day 3 saw +5.83%, day 5 +4.12%—but momentum has faded as the margin-compression story and subsidy risk sank in. Current price ₹147.82 sits above the 20-day, 50-day, and 200-day moving averages (₹145.77, ₹140.30, ₹137.27 respectively), suggesting buyers are still in control, but the stock is 18.24% off its all-time high of ₹180.80 and volume is declining. That suggests the pop was real, but the street is not chasing higher.
The ownership picture is shifting quietly: FII holdings fell 3.26 percentage points to 5.10% (from 15.01% a year ago), a consistent retreat over the last four quarters. DII has stepped in (now 18.08%, up 2.59pp quarter-on-quarter), and the promoter remains stable at 57.86%. The bulk trades on Jul 29 show no insider-linked selling near highs, but the FII exit is a yellow flag—large institutions may be rotating out of commodity-exposed industrials into more stable growth plays.
Raw-material cost volatility (sulphur $1,000+/MT vs $850 Q1 avg)
HighSulphur up 18% in 3 months, spot basis only (no hedges). 70–75% of global supply trades via Strait of Hormuz (geopolitical risk). Every ₹10/MT move in raw materials compresses ₹5,000/MT normalized EBITDA. Sustained elevation kills the margin thesis.
Subsidy receivable concentration (₹4,600 Cr = 75% of Q1 PAT)
HighOutstanding subsidy creates working-capital drag. Government payment delays would severely impact liquidity. Q1 collections ₹2,650 Cr (22% higher YoY) provide some comfort, but policy-driven timing remains a risk. If government budget stress rises, collections could slow.
Government DAP price caps (₹1,350/bag fixed)
HighPrice cap prevents pass-through of cost inflation to farmers. Company shifted volume to DAP (+55% Q1) for profitability, but cannot raise prices further. If subsidy is withheld or reduced, margin compression is forced, not optional.
Normalized EBITDA miss risk (₹5,000/MT conditional guidance)
MediumGuidance depends on cost stabilization AND government subsidy support. Neither is guaranteed. If raw materials stay elevated or government shifts policy, ₹5,000/MT is aspirational, not a floor.
Capacity project execution (₹3,500–3,600 Cr big expansion FY29–30)
MediumMulti-year capex is dependent on macro conditions (financing, raw-material prices, demand). Delays would defer earnings uplift. Phase-I (phos acid ramp) is on track, but larger capex is unproven in an inflationary environment.
Backward-integration strategy delivering tangible cost savings (sulph acid +32%, phos acid +7%)
Market share gains sustained (+13% volume growth vs. +1% industry phosphatic)
Concrete capex roadmap (Phase-I on track, AlF3 approved, big expansion Q2 FY29)
Management transparent on inventory benefit and margin normalization
Q1 EBITDA ₹7,000/MT is inventory-aided; normalized ₹5,000/MT is -29% headwind
Sulphur volatility (spot basis, no hedges) and geopolitical risk (Hormuz) create near-term pressure
Subsidy receivable ₹4,600 Cr (75% of PAT) exposed to government payment timing
Government DAP price caps prevent pricing relief; pass-through limited
FII holdings fell 3.26pp YoY; institutional confidence waning
1 · Q2 & Q3 EBITDA run-rate
Once inventory benefit is exhausted, the normalized EBITDA story becomes testable. Watch for ₹5,000/MT guidance credibility. Sulphur and ammonia price moves will frame this. If raw materials cool, management credibility improves; if not, a miss is likely.
2 · Subsidy collection trend (Q2–Q3)
Monitor outstanding subsidy and quarterly collections. Any slowdown from the 22% growth seen in Q1 would signal government payment stress. The ₹4,600 Cr overhang needs steady liquidation.
3 · Phosphoric acid Phase-I ramp (Dec FY27 and Aug FY28 milestones)
Equipment ordering and contract awards are on track. Watch for delays or cost overruns. Dec FY27 (1 lakh tons) is the first checkpoint; Aug FY28 (final 1 lakh tons) closes the loop. Execution risk is low, but a slip would challenge the broader capex timeline.
4 · AlF3 plant progress (22–24 month timeline)
Commissioning target places the plant as a potential FY28 Q4 catalyst. Watch for capex spend tracking and any demand validation updates (B2B sales to aluminum smelters in Odisha).
Paradeep's Q1 is a steady quarter masking a near-term squeeze. The backward-integration thesis is real, volumes are growing faster than the market, and the company has a concrete 3-year capex roadmap. But the headline profit is inventory-aided, the normalized EBITDA target is conditional on external factors (raw-material costs and government support) that are beyond management's control, and the subsidy receivable is a working-capital sword. The stock's current position—above key moving averages but off its highs, with declining volume—reflects this complexity: not a bargain, not a sell, but not a compelling buy until the margin-compression story is clearer.
Watch Q2 and Q3 for the real EBITDA run-rate. If sulphur stabilizes and subsidy collections hold, the ₹5,000/MT normalized target is credible and the long-term capex story stays intact. If raw materials stay elevated or government payments slow, the street will reprice the stock lower. The key number to track from here is quarterly EBITDA per ton—it's the single best proxy for whether the company's normalized guidance is a floor or a ceiling.